Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is (1) to determine if rituximab induction therapy followed by
glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by
GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple
sclerosis (RMS).